Multiple studies have shown that c-Met is overexpressed in a range of different cancers, including colorectal cancer [5], breast [6], lung [7], pancreatic [8], prostate [9], gastric [10], renal [11], ovarian cancer [12], melanoma [13], nervous system malignancies [14], and pediatric tumours [15], making it a valuable target for cancer therapy. This evidence concerns the gene MET and cancer.